Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597363 | 0.91 | TSHR (0.57) | TNFGAAMAPTTSHRCYP1A2 | |
| SCHEMBL597863 | 0.83 | TSHR (0.40) | TNFGAAMAPTTSHRCYP1A2 | |
| SCHEMBL3564687 | 0.80 | TSHR (0.47) | TNFGAAMAPTTSHRCYP1A2 | |
| SCHEMBL598195 | 0.80 | CYSLTR2 (0.43) | TNFGAALMNACYSLTR2CYSLTR1 | |
| SCHEMBL598096 | 0.78 | CYSLTR2 (0.55) | TNFCYSLTR2CYSLTR1 | |
| SCHEMBL597651 | 0.78 | MCL1 (0.54) | TNFGAAMAPTTSHRCYP1A2 | |
| SCHEMBL597856 | 0.75 | CYSLTR2 (0.59) | TNFCYSLTR2CYSLTR1 | |
| SCHEMBL28334299 | 0.75 | CYP4F2 (0.46) | TNFGAACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3748048 | 0.74 | HSD17B10 (0.47) | TNFGAAMAPTTSHRCYP1A2 | |
| SCHEMBL3721634 | 0.74 | TNF (0.53) | TNFGAACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583964-B1 | NEW CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO PHARMACEUTICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-8598223-B2 | Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2583964-A1 | NOVEL CRYSTALLINE FORMS OF 4,4'-[4-FLUORO-7-({4-[4-(3-FLUORO-2-METHYLPHENYL)BUTOXY]PHENYL}ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, 4,4'-[2-METHYL-7-({4-[4-(PENTAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7-({4-[4-(2,3,4,6-TETRAFLUOROPHENYL)BUTOXY]PHENYL}ETHYNYL)-1H-INDOLE-1,3-DIYL]DIBUTANOIC ACID | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | disclosed |
| EP-2206698-B1 | Ethynylindole compounds | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090482-A1 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID | IDO1, HTR3C, HTR5A | TNF 4248/4885GAA 4411/4885MAPT 1315/4885 |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | CYSLTR2, CYSLTR1, LTB4R2 | TNF 2011/4885GAA 4840/4885MAPT 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.